Accepted for Publication: April 12, 2013.
Published Online: August 14, 2013. doi:10.1001/jamadermatol.2013.4909.
Study concept and design: Patel, Simpson, Hanifin.
Acquisition of data: Patel, Hill.
Analysis and interpretation of data: Patel, Simpson, Hanifin.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: Patel, Simpson, Hanifin.
Statistical analysis: Patel.
Obtained funding: Patel.
Administrative, technical, and material support: Hill, Hanifin.
Study supervision: Hanifin.
Conflict of Interest Disclosures: Dr Hanifin reported serving as a consultant to Chugai Pharma USA, GlaxoSmithKline, Leerink Swann, LEO Pharma, Meda Pharmaceuticals, Merck Sharp & Dohme, Novartis, Pfizer, Valeant Elidel Advisory Board, and ZymoGenetics/BMS. Dr Simpson reported serving as a consultant to Alcimed, Asubio, Brickell Biotech, Clarion Healthcare, Galderma Laboratories, L.E.K. Consulting, Medicis Pharmaceutical Corp, Panmira Pharmaceuticals LLC, Regeneron, and Versant Ventures. Dr Simpson reported serving as a speaker for Galderma Laboratories.
Funding/Support: This study was supported in part by the Department of Dermatology, Oregon Health & Science University.
Role of the Sponsors: The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data; or in the preparation, review, or approval of the manuscript.
Additional Contributions: We thank the Department of Dermatology, Oregon Health & Science University, Samuel Bremmer, MD, and Christine Carocci.